Literature DB >> 24922550

Early experience with multiparametric magnetic resonance imaging-targeted biopsies under visual transrectal ultrasound guidance in patients suspicious for prostate cancer undergoing repeated biopsy.

Lars Boesen1, Nis Noergaard, Elizaveta Chabanova, Vibeke Logager, Ingegerd Balslev, Kari Mikines, Henrik S Thomsen.   

Abstract

OBJECTIVES: The purpose of this study was to investigate the detection rate of prostate cancer (PCa) by multiparametric magnetic resonance imaging-targeted biopsies (mp-MRI-bx) in patients with prior negative transrectal ultrasound biopsy (TRUS-bx) sessions without previous experience of this.
MATERIAL AND METHODS: Eighty-three patients with prior negative TRUS-bx scheduled for repeated biopsies due to persistent suspicion of PCa were prospectively enrolled. mp-MRI was performed before biopsy and all lesions were scored according to the Prostate Imaging Reporting and Data System (PI-RADS) and Likert classification. All underwent repeated TRUS-bx (10 cores) and mp-MRI-bx under visual TRUS guidance of any mp-MRI-suspicious lesion not targeted by systematic TRUS-bx.
RESULTS: PCa was found in 39 out of 83 patients (47%) and mp-MRI identified at least one lesion with some degree of suspicion in all 39 patients. Both PI-RADS and Likert scoring showed a high correlation between suspicion of malignancy and biopsy results (p < 0.0001). Five patients (13%) had cancer detected only on mp-MRI-bx outside the TRUS-bx areas (p = 0.025) and another seven patients (21%) had an overall Gleason score upgrade of at least one grade based on the mp-MRI-bx. Secondary PCa lesions not visible on mp-MRI were detected by TRUS-bx in six out of 39 PCa patients. The secondary foci were all Gleason 6 (3 + 3) in 5-10% of the biopsy core. According to the Epstein criteria, 37 out of 39 cancer patients were classified as clinically significant.
CONCLUSION: Using mp-MRI, even without previous experience, can improve the detection rate of significant PCa at repeated biopsy and allows more accurate Gleason grading.

Entities:  

Keywords:  multiparametric MRI; prostate biopsy; prostate cancer; targeted biopsy; transrectal ultrasound; visual fusion

Mesh:

Substances:

Year:  2014        PMID: 24922550     DOI: 10.3109/21681805.2014.925497

Source DB:  PubMed          Journal:  Scand J Urol        ISSN: 2168-1805            Impact factor:   1.612


  5 in total

1.  Prostate cancer staging with extracapsular extension risk scoring using multiparametric MRI: a correlation with histopathology.

Authors:  Lars Boesen; Elizaveta Chabanova; Vibeke Løgager; Ingegerd Balslev; Kari Mikines; Henrik S Thomsen
Journal:  Eur Radiol       Date:  2014-12-11       Impact factor: 5.315

Review 2.  Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis.

Authors:  E J Bass; A Pantovic; M J Connor; S Loeb; A R Rastinehad; M Winkler; Rhian Gabe; H U Ahmed
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-09-21       Impact factor: 5.455

Review 3.  Current and Emerging Clinical Applications of Multispectral Optoacoustic Tomography (MSOT) in Oncology.

Authors:  Lacey R McNally; Megan Mezera; Desiree E Morgan; Peter J Frederick; Eddy S Yang; Isam-Eldin Eltoum; William E Grizzle
Journal:  Clin Cancer Res       Date:  2016-05-20       Impact factor: 12.531

4.  A Prospective Study on the Efficacy of Cognitive Targeted Transrectal Ultrasound Prostate Biopsy in Diagnosing Clinically Significant Prostate Cancer.

Authors:  Mathisekaran Thangarasu; Sanjay Prakash Jayaprakash; Nivash Selvaraj; Sandeep Bafna; Rajesh Paul; Chandranathan Mahesh; Nitesh Jain; Arunkumar Balakrishnan; Ananthakrishnan Sivaraman
Journal:  Res Rep Urol       Date:  2021-05-05

Review 5.  23 Na-MRI as a Noninvasive Biomarker for Cancer Diagnosis and Prognosis.

Authors:  Linda Osei Poku; M Phil; Yongna Cheng; Kai Wang; Xilin Sun
Journal:  J Magn Reson Imaging       Date:  2020-03-26       Impact factor: 4.813

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.